EVERTOR

Main information

  • Trade name:
  • EVERTOR 3*10
  • Dosage:
  • 5MG
  • Composition:
  • 3*10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EVERTOR 3*10
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

13-2-2018

Opinion/decision on a Paediatric investigation plan (PIP):    Votubia, Everolimus, Therapeutic area: Neurology

Opinion/decision on a Paediatric investigation plan (PIP): Votubia, Everolimus, Therapeutic area: Neurology

Europe - EFSA - European Food Safety Authority EFSA Journal

26-1-2018

ZORTRESS (Everolimus) Tablet [Novartis Pharmaceuticals Corporation]

ZORTRESS (Everolimus) Tablet [Novartis Pharmaceuticals Corporation]

Updated Date: Jan 26, 2018 EST

US - DailyMed

11-5-2017

Long-Lasting Effect of Everolimus in Tuberous Sclerosis

Long-Lasting Effect of Everolimus in Tuberous Sclerosis

Improvements in seizures documented earlier in patients with tuberous sclerosis complex (TSC) taking everolimus (Afinitor, Novartis) in the phase 3 EXIST-3 trial have continued during an open-label extension phase of the trial.

US - RxList